SAGE-547
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Super-Refractory Status Epilepticus
Conditions
Super-Refractory Status Epilepticus
Trial Timeline
— → —
NCT ID
NCT02433314About SAGE-547
SAGE-547 is a pre-clinical stage product being developed by Supernus Pharmaceuticals for Super-Refractory Status Epilepticus. The current trial status is completed. This product is registered under clinical trial identifier NCT02433314. Target conditions include Super-Refractory Status Epilepticus.
Hype Score Breakdown
Clinical
5
Activity
2
Company
5
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02433314 | Pre-clinical | Completed |
| NCT02285504 | Phase 2 | Completed |
| NCT02052739 | Phase 1/2 | Completed |
Competing Products
2 competing products in Super-Refractory Status Epilepticus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SAGE-547 | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 3 | 72 |